Cargando…
Optimal Molecular Methods in Detecting p190(BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature
Patients with BCR-ABL1 positive hematologic malignancies and Philadelphia-like B-lymphoblastic leukemia (B-ALL) are potential candidates for targeted therapy with tyrosine kinase inhibitors (TKI). Before TKIs, patients with B-ALL had a much worse prognosis and current treatments with targeted TKI th...
Autores principales: | Sonu, Rebecca J., Jonas, Brian A., Dwyre, Denis M., Gregg, Jeffrey P., Rashidi, Hooman H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407518/ https://www.ncbi.nlm.nih.gov/pubmed/25949834 http://dx.doi.org/10.1155/2015/458052 |
Ejemplares similares
-
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007) -
Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome
por: Ali, Saba F., et al.
Publicado: (2015) -
Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy
por: Kim, Heejeong, et al.
Publicado: (2023) -
KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia
por: Zhang, Cuiping, et al.
Publicado: (2018) -
The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia
por: Carrà, Giovanna, et al.
Publicado: (2016)